EP3430023A1 — Polymorphic forms of sofosbuvir
Assigned to Mylan Laboratories Ltd · Expires 2019-01-23 · 7y expired
What this patent protects
The present disclosure provides novel crystalline sofosbuvir form- M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage forms. Formula (1): Sofosbuvir
USPTO Abstract
The present disclosure provides novel crystalline sofosbuvir form- M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage forms. Formula (1): Sofosbuvir
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.